Cargando…

Efficacy of Flecainide in Catecholaminergic Polymorphic Ventricular Tachycardia Is Mutation-Independent but Reduced by Calcium Overload

BACKGROUND: The dual Na(+) and cardiac Ca(2+)-release channel inhibitor, Flecainide (FLEC) is effective in patients with catecholaminergic polymorphic ventricular tachycardia (CPVT), a disease caused by mutations in cardiac Ca(2+)-release channels (RyR2), calsequestrin (Casq2), or calmodulin. FLEC s...

Descripción completa

Detalles Bibliográficos
Autores principales: Hwang, Hyun Seok, Baldo, Marcelo P., Rodriguez, Jose Pindado, Faggioni, Michela, Knollmann, Bjorn C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6701460/
https://www.ncbi.nlm.nih.gov/pubmed/31456692
http://dx.doi.org/10.3389/fphys.2019.00992
_version_ 1783445064588984320
author Hwang, Hyun Seok
Baldo, Marcelo P.
Rodriguez, Jose Pindado
Faggioni, Michela
Knollmann, Bjorn C.
author_facet Hwang, Hyun Seok
Baldo, Marcelo P.
Rodriguez, Jose Pindado
Faggioni, Michela
Knollmann, Bjorn C.
author_sort Hwang, Hyun Seok
collection PubMed
description BACKGROUND: The dual Na(+) and cardiac Ca(2+)-release channel inhibitor, Flecainide (FLEC) is effective in patients with catecholaminergic polymorphic ventricular tachycardia (CPVT), a disease caused by mutations in cardiac Ca(2+)-release channels (RyR2), calsequestrin (Casq2), or calmodulin. FLEC suppresses spontaneous Ca(2+) waves in Casq2-knockout (Casq2(−/−)) cardiomyocytes, a CPVT model. However, a report failed to find FLEC efficacy against Ca(2+) waves in another CPVT model, RyR2-R4496C heterozygous mice (RyR2(R4496C+/−)), raising the possibility that FLEC efficacy may be mutation dependent. OBJECTIVE: To address this controversy, we compared FLEC in Casq2(−/−) and RyR2(R4496C+/−) cardiomyocytes and mice under identical conditions. METHODS: After 30 min exposure to FLEC (6 μM) or vehicle (VEH), spontaneous Ca(2+) waves were quantified during a 40 s pause after 1 Hz pacing train in the presence of isoproterenol (ISO, 1 μM). FLEC efficacy was also tested in vivo using a low dose (LOW: 3 mg/kg ISO + 60 mg/kg caffeine) or a high dose catecholamine challenge (HIGH: 3 mg/kg ISO + 120 mg/kg caffeine). RESULTS: In cardiomyocytes, FLEC efficacy was dependent on extracellular [Ca(2+)]. At 2 mM [Ca(2+)], only Casq2(−/−) myocytes exhibited Ca(2+) waves, which were strongly suppressed by FLEC. At 3 mM [Ca(2+)] both groups exhibited Ca(2+) waves that were suppressed by FLEC. At 4 mM [Ca(2+)], FLEC no longer suppressed Ca(2+) waves in both groups. Analogous to the results in myocytes, RyR2(R4496C+/−) mice (n = 12) had significantly lower arrhythmia scores than Casq2(−/−) mice (n = 9), but the pattern of FLEC efficacy was similar in both groups (i.e., reduced FLEC efficacy after HIGH dose catecholamine challenge). CONCLUSION: FLEC inhibits Ca(2+) waves in RyR2(R4496C+/−) cardiomyocytes, indicating that RyR2 channel block by FLEC is not mutation-specific. However, FLEC efficacy is reduced by Ca(2+) overload in vitro or by high dose catecholamine challenge in vivo, which could explain conflicting literature reports.
format Online
Article
Text
id pubmed-6701460
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-67014602019-08-27 Efficacy of Flecainide in Catecholaminergic Polymorphic Ventricular Tachycardia Is Mutation-Independent but Reduced by Calcium Overload Hwang, Hyun Seok Baldo, Marcelo P. Rodriguez, Jose Pindado Faggioni, Michela Knollmann, Bjorn C. Front Physiol Physiology BACKGROUND: The dual Na(+) and cardiac Ca(2+)-release channel inhibitor, Flecainide (FLEC) is effective in patients with catecholaminergic polymorphic ventricular tachycardia (CPVT), a disease caused by mutations in cardiac Ca(2+)-release channels (RyR2), calsequestrin (Casq2), or calmodulin. FLEC suppresses spontaneous Ca(2+) waves in Casq2-knockout (Casq2(−/−)) cardiomyocytes, a CPVT model. However, a report failed to find FLEC efficacy against Ca(2+) waves in another CPVT model, RyR2-R4496C heterozygous mice (RyR2(R4496C+/−)), raising the possibility that FLEC efficacy may be mutation dependent. OBJECTIVE: To address this controversy, we compared FLEC in Casq2(−/−) and RyR2(R4496C+/−) cardiomyocytes and mice under identical conditions. METHODS: After 30 min exposure to FLEC (6 μM) or vehicle (VEH), spontaneous Ca(2+) waves were quantified during a 40 s pause after 1 Hz pacing train in the presence of isoproterenol (ISO, 1 μM). FLEC efficacy was also tested in vivo using a low dose (LOW: 3 mg/kg ISO + 60 mg/kg caffeine) or a high dose catecholamine challenge (HIGH: 3 mg/kg ISO + 120 mg/kg caffeine). RESULTS: In cardiomyocytes, FLEC efficacy was dependent on extracellular [Ca(2+)]. At 2 mM [Ca(2+)], only Casq2(−/−) myocytes exhibited Ca(2+) waves, which were strongly suppressed by FLEC. At 3 mM [Ca(2+)] both groups exhibited Ca(2+) waves that were suppressed by FLEC. At 4 mM [Ca(2+)], FLEC no longer suppressed Ca(2+) waves in both groups. Analogous to the results in myocytes, RyR2(R4496C+/−) mice (n = 12) had significantly lower arrhythmia scores than Casq2(−/−) mice (n = 9), but the pattern of FLEC efficacy was similar in both groups (i.e., reduced FLEC efficacy after HIGH dose catecholamine challenge). CONCLUSION: FLEC inhibits Ca(2+) waves in RyR2(R4496C+/−) cardiomyocytes, indicating that RyR2 channel block by FLEC is not mutation-specific. However, FLEC efficacy is reduced by Ca(2+) overload in vitro or by high dose catecholamine challenge in vivo, which could explain conflicting literature reports. Frontiers Media S.A. 2019-08-13 /pmc/articles/PMC6701460/ /pubmed/31456692 http://dx.doi.org/10.3389/fphys.2019.00992 Text en Copyright © 2019 Hwang, Baldo, Rodriguez, Faggioni and Knollmann. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Physiology
Hwang, Hyun Seok
Baldo, Marcelo P.
Rodriguez, Jose Pindado
Faggioni, Michela
Knollmann, Bjorn C.
Efficacy of Flecainide in Catecholaminergic Polymorphic Ventricular Tachycardia Is Mutation-Independent but Reduced by Calcium Overload
title Efficacy of Flecainide in Catecholaminergic Polymorphic Ventricular Tachycardia Is Mutation-Independent but Reduced by Calcium Overload
title_full Efficacy of Flecainide in Catecholaminergic Polymorphic Ventricular Tachycardia Is Mutation-Independent but Reduced by Calcium Overload
title_fullStr Efficacy of Flecainide in Catecholaminergic Polymorphic Ventricular Tachycardia Is Mutation-Independent but Reduced by Calcium Overload
title_full_unstemmed Efficacy of Flecainide in Catecholaminergic Polymorphic Ventricular Tachycardia Is Mutation-Independent but Reduced by Calcium Overload
title_short Efficacy of Flecainide in Catecholaminergic Polymorphic Ventricular Tachycardia Is Mutation-Independent but Reduced by Calcium Overload
title_sort efficacy of flecainide in catecholaminergic polymorphic ventricular tachycardia is mutation-independent but reduced by calcium overload
topic Physiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6701460/
https://www.ncbi.nlm.nih.gov/pubmed/31456692
http://dx.doi.org/10.3389/fphys.2019.00992
work_keys_str_mv AT hwanghyunseok efficacyofflecainideincatecholaminergicpolymorphicventriculartachycardiaismutationindependentbutreducedbycalciumoverload
AT baldomarcelop efficacyofflecainideincatecholaminergicpolymorphicventriculartachycardiaismutationindependentbutreducedbycalciumoverload
AT rodriguezjosepindado efficacyofflecainideincatecholaminergicpolymorphicventriculartachycardiaismutationindependentbutreducedbycalciumoverload
AT faggionimichela efficacyofflecainideincatecholaminergicpolymorphicventriculartachycardiaismutationindependentbutreducedbycalciumoverload
AT knollmannbjornc efficacyofflecainideincatecholaminergicpolymorphicventriculartachycardiaismutationindependentbutreducedbycalciumoverload